Imaging study for HER2-positive cancers using a special tracer
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This study uses a radioactive tracer to take pictures of tumors that have a protein called HER2. It may help doctors see where the cancer is in your body and could guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with stomach, breast, or bladder cancer that is HER2-positive.
- You must have at least one tumor that can be measured on scans.
- You must be between 18 and 75 years old.
- Your blood counts, liver, and kidney function must meet certain levels.
- You must not be pregnant and must agree to use birth control during the study.
- You must be able to lie still for a PET/CT scan and not be allergic to the tracer ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.